FDA authorises Covid antibody treatment for those at risk of severe illness

The US Food and Drug Administration (FDA) has approved emergency use of a preventive monoclonal antibody treatment to protect those who are vulnerable to coronavirus.

The agency said in a press release last week that it had authorised the emergency use of REGEN-COV in adults and pediatric individuals who are at high risk for progression to severe Covid-19.

The antibody is only permitted to be used only after exposure to the virus and is said to be the first time an injectable antibody treatment has been approved for the prevention of Covid-19 post-exposure.